Literature DB >> 24251580

Regulation of hypoxia-induced pulmonary hypertension by vascular smooth muscle hypoxia-inducible factor-1α.

Molly K Ball1, Gregory B Waypa, Paul T Mungai, Jacqueline M Nielsen, Lyubov Czech, V Joseph Dudley, Lauren Beussink, Robert W Dettman, Sara K Berkelhamer, Robin H Steinhorn, Sanjiv J Shah, Paul T Schumacker.   

Abstract

RATIONALE: Chronic hypoxia induces pulmonary vascular remodeling, pulmonary hypertension, and right ventricular hypertrophy. At present, little is known about mechanisms driving these responses. Hypoxia-inducible factor-1α (HIF-1α) is a master regulator of transcription in hypoxic cells, up-regulating genes involved in energy metabolism, proliferation, and extracellular matrix reorganization. Systemic loss of a single HIF-1α allele has been shown to attenuate hypoxic pulmonary hypertension, but the cells contributing to this response have not been identified.
OBJECTIVES: We sought to determine the contribution of HIF-1α in smooth muscle on pulmonary vascular and right heart responses to chronic hypoxia.
METHODS: We used mice with homozygous conditional deletion of HIF-1α combined with tamoxifen-inducible smooth muscle-specific Cre recombinase expression. Mice received either tamoxifen or vehicle followed by exposure to either normoxia or chronic hypoxia (10% O2) for 30 days before measurement of cardiopulmonary responses.
MEASUREMENTS AND MAIN RESULTS: Tamoxifen-induced smooth muscle-specific deletion of HIF-1α attenuated pulmonary vascular remodeling and pulmonary hypertension in chronic hypoxia. However, right ventricular hypertrophy was unchanged despite attenuated pulmonary pressures.
CONCLUSIONS: These results indicate that HIF-1α in smooth muscle contributes to pulmonary vascular remodeling and pulmonary hypertension in chronic hypoxia. However, loss of HIF-1 function in smooth muscle does not affect hypoxic cardiac remodeling, suggesting that the cardiac hypertrophy response is not directly coupled to the increase in pulmonary artery pressure.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24251580      PMCID: PMC3977726          DOI: 10.1164/rccm.201302-0302OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  52 in total

1.  Selected Contribution: Pulmonary hypertension in mice following intermittent hypoxia.

Authors:  K A Fagan
Journal:  J Appl Physiol (1985)       Date:  2001-06

2.  Pulmonary artery adventitial fibroblasts cooperate with vasa vasorum endothelial cells to regulate vasa vasorum neovascularization: a process mediated by hypoxia and endothelin-1.

Authors:  Neil J Davie; Evgenia V Gerasimovskaya; Stephen E Hofmeister; Aaron P Richman; Peter L Jones; John T Reeves; Kurt R Stenmark
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

Review 3.  Hypoxic activation of adventitial fibroblasts: role in vascular remodeling.

Authors:  Kurt R Stenmark; Evgenia Gerasimovskaya; Raphael A Nemenoff; Mita Das
Journal:  Chest       Date:  2002-12       Impact factor: 9.410

4.  Defective carotid body function and impaired ventilatory responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1 alpha.

Authors:  David D Kline; Ying-Jie Peng; Dominador J Manalo; Gregg L Semenza; Nanduri R Prabhakar
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-15       Impact factor: 11.205

5.  Digoxin inhibits development of hypoxic pulmonary hypertension in mice.

Authors:  Edsel M Abud; Julie Maylor; Clark Undem; Arjun Punjabi; Ari L Zaiman; Allen C Myers; J T Sylvester; Gregg L Semenza; Larissa A Shimoda
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-09       Impact factor: 11.205

6.  Heart and lung VEGF mRNA expression in rats with monocrotaline- or hypoxia-induced pulmonary hypertension.

Authors:  C Partovian; S Adnot; S Eddahibi; E Teiger; M Levame; P Dreyfus; B Raffestin; C Frelin
Journal:  Am J Physiol       Date:  1998-12

Review 7.  Secondary pulmonary hypertension.

Authors:  Rahul Roy; Jonathan M Couriel
Journal:  Paediatr Respir Rev       Date:  2006-01-30       Impact factor: 2.726

8.  Hypoxia-inducible factor-1α in pulmonary artery smooth muscle cells lowers vascular tone by decreasing myosin light chain phosphorylation.

Authors:  Yu-Mee Kim; Elizabeth A Barnes; Cristina M Alvira; Lihua Ying; Sushma Reddy; David N Cornfield
Journal:  Circ Res       Date:  2013-03-19       Impact factor: 17.367

Review 9.  The a"MAZE"ing world of lung-specific transgenic mice.

Authors:  Emma L Rawlins; Anne-Karina Perl
Journal:  Am J Respir Cell Mol Biol       Date:  2011-12-28       Impact factor: 6.914

10.  Significant Differences in Markers of Oxidant Injury between Idiopathic and Bronchopulmonary-Dysplasia-Associated Pulmonary Hypertension in Children.

Authors:  Kimberly B Vera; Donald Moore; English Flack; Michael Liske; Marshall Summar
Journal:  Pulm Med       Date:  2012-07-05
View more
  104 in total

Review 1.  Update in Pulmonary Vascular Diseases 2014.

Authors:  Elena A Goncharova; Mark T Gladwin; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2015-09-01       Impact factor: 21.405

2.  Time-dependent PPARγ Modulation of HIF-1α Signaling in Hypoxic Pulmonary Artery Smooth Muscle Cells.

Authors:  Justine I Blum; Kaiser M Bijli; Tamara C Murphy; Jennifer M Kleinhenz; C Michael Hart
Journal:  Am J Med Sci       Date:  2016-04-04       Impact factor: 2.378

Review 3.  HIF and pulmonary vascular responses to hypoxia.

Authors:  Larissa A Shimoda; Steven S Laurie
Journal:  J Appl Physiol (1985)       Date:  2013-12-12

Review 4.  Transglutaminase 2-mediated serotonylation in pulmonary hypertension.

Authors:  K C Penumatsa; B L Fanburg
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-12-27       Impact factor: 5.464

5.  Let's Talk about Sex: A Novel Mechanism by Which Estrogen Receptor β Limits Hypoxia-Inducible Factor Expression in Pulmonary Endothelial Cells.

Authors:  Larissa A Shimoda
Journal:  Am J Respir Cell Mol Biol       Date:  2018-07       Impact factor: 6.914

6.  Implication of in vivo circulating fibrocytes ablation in experimental pulmonary hypertension murine model.

Authors:  Vandana S Nikam; Sandeep Nikam; Akyl Sydykov; Katrin Ahlbrecht; Rory E Morty; Werner Seeger; Robert Voswinckel
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

7.  Thiol-Redox Regulation in Lung Development and Vascular Remodeling.

Authors:  Gaston Ofman; Trent E Tipple
Journal:  Antioxid Redox Signal       Date:  2019-03-04       Impact factor: 8.401

Review 8.  The molecular rationale for therapeutic targeting of glutamine metabolism in pulmonary hypertension.

Authors:  Thomas Bertero; Dror Perk; Stephen Y Chan
Journal:  Expert Opin Ther Targets       Date:  2019-05-11       Impact factor: 6.902

9.  Divergent changes of p53 in pulmonary arterial endothelial and smooth muscle cells involved in the development of pulmonary hypertension.

Authors:  Ziyi Wang; Kai Yang; Qiuyu Zheng; Chenting Zhang; Haiyang Tang; Aleksandra Babicheva; Qian Jiang; Meichan Li; Yuqin Chen; Shane G Carr; Kang Wu; Qian Zhang; Angela Balistrieri; Christina Wang; Shanshan Song; Ramon J Ayon; Ankit A Desai; Stephen M Black; Joe G N Garcia; Ayako Makino; Jason X-J Yuan; Wenju Lu; Jian Wang
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-10-25       Impact factor: 5.464

10.  Loss of microRNA-17∼92 in smooth muscle cells attenuates experimental pulmonary hypertension via induction of PDZ and LIM domain 5.

Authors:  Tianji Chen; Guofei Zhou; Qiyuan Zhou; Haiyang Tang; Joyce Christina F Ibe; Hongqiang Cheng; Deming Gou; Ju Chen; Jason X-J Yuan; J Usha Raj
Journal:  Am J Respir Crit Care Med       Date:  2015-03-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.